Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Avastin (Bevacizumab) for Cervical Cancer

Proposed for use in combination with first-line current care chemotherapy for metastatic or recurrent cervical cancer not amenable to curative treatment with surgery and/or radiotherapy.

Orbactiv (Oritavancin)

An intravenous semisynthetic lipoglycopeptide antibiotic administered in a 1-dose regimen to treat acute bacterial skin and skin structure infections in adults.

Phasix Mesh for Hernia Repair

A monofilament, fully resorbable surgical mesh for abdominal hernia repair intended as an alternative to biologic mesh.

Acessa System

A device to perform minimally invasive radiofrequency ablation of uterine fibroids under laparoscopic ultrasound guidance.

Cyramza (Ramucirumab)

An intravenous angiogenesis inhibitor for second-line treatment of advanced gastric or gastroesophageal junction cancer.